SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-20-010083
Filing Date
2020-09-15
Accepted
2020-09-15 08:36:55
Documents
6
Period of Report
2020-09-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sbfm_8k.htm 8-K 26823
2 FINANCING AGREEMENT WITH RB CAPITAL PARTNERS, INC. sbfm_ex1015.htm EX-10.15 2583
3 PRESS RELEASE sbfm_ex991.htm EX-99.1 13569
4 IMAGE sbfm_ex1015000.jpg GRAPHIC 104231
5 IMAGE sbfm_ex1015001.jpg GRAPHIC 33174
6 IMAGE sbfm_logo.jpg GRAPHIC 9208
  Complete submission text file 0001654954-20-010083.txt   246736
Mailing Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5
Business Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5 514-426-6161
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

IRS No.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52898 | Film No.: 201174779
SIC: 8731 Services-Commercial Physical & Biological Research